• UCB will present 18 accepted abstracts on rheumatic diseases at the American College of Rheumatology congress in 2026.
• Interim FASTRAX findings will evaluate patient outcomes and experiences across standard care and patient-initiated follow-up for axial spondyloarthritis.
• The digital platform lets clinically stable patients monitor symptoms at home and seek support when needed, aiming to improve service efficiency.
• Research will also cover the first application of TRM-SLE, a lupus treatment-response measure designed to complement existing measures; further validation is needed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.